Related references
Note: Only part of the references are listed.Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
Lapo Alinari et al.
BLOOD (2011)
Insulin-Like Growth Factor-I Receptor Blockade Reduces Tumor Angiogenesis and Enhances the Effects of Bevacizumab for a Human Gastric Cancer Cell Line, MKN45
Hua Li et al.
CANCER (2011)
Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations
Marcus Fischer et al.
CANCER RESEARCH (2011)
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Ritwik Ghosh et al.
CANCER RESEARCH (2011)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Anti-IL-23 Monoclonal Antibody Synergizes in Combination with Targeted Therapies or IL-2 to Suppress Tumor Growth and Metastases
Michele W. L. Teng et al.
CANCER RESEARCH (2011)
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Dana D. Hu-Lowe et al.
CANCER RESEARCH (2011)
DUAL INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR AND INSULIN-LIKE GROWTH FACTOR RECEPTOR I: REDUCTION OF ANGIOGENESIS AND TUMOR GROWTH IN CUTANEOUS SQUAMOUS CELL CARCINOMA
Chad E. Galer et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity
Jianying Dong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
Jianying Dong et al.
MABS (2011)
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
Stuart L. Emanuel et al.
MABS (2011)
Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor Growth
Valery Krasnoperov et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2010)
A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL
Bart A. Nijmeijer et al.
BLOOD (2010)
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis
Jude Canon et al.
BONE (2010)
Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization
Denis Tvorogov et al.
CANCER CELL (2010)
Receptor Tyrosine Kinase Coactivation Networks in Cancer
Alexander M. Xu et al.
CANCER RESEARCH (2010)
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
Birgit Schoeberl et al.
CANCER RESEARCH (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Carlos Bais et al.
CELL (2010)
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
Sara Van de Veire et al.
CELL (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors
Peter J. Rosen et al.
CLINICAL CANCER RESEARCH (2010)
Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu et al.
CLINICAL CANCER RESEARCH (2010)
Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma
Allyson J. Ocean et al.
CLINICAL COLORECTAL CANCER (2010)
The Role of Anti-Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Therapies in the Treatment of Non-Small-Cell Lung Cancer
Corey Langer et al.
CLINICAL LUNG CANCER (2010)
Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation
Annie Yang et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
TAM receptor signaling and autoimmune disease
Carla V. Rothlin et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Enhanced Cancer Therapy with the Combination of EGFR and VEGFR-2 Targeting in an Orthotopic Glioblastoma Model
Yi Diao et al.
JOURNAL OF CHEMOTHERAPY (2010)
Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer
Diane Lauren Reidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
Kazuyoshi Takeda et al.
JOURNAL OF IMMUNOLOGY (2010)
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Sara M. Mangsbo et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Biologic Modulation of Chemotherapy in Patients With Hepatic Colorectal Metastases: The Role of Anti-VEGF and Anti-EGFR Antibodies
Ravit Geva et al.
JOURNAL OF SURGICAL ONCOLOGY (2010)
Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response
Jianying Dong et al.
MOLECULAR CANCER THERAPEUTICS (2010)
TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
Wataru Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Jeffrey L. Brown et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody
Angela Coxon et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Chronic DLL4 blockade induces vascular neoplasms
Minhong Yan et al.
NATURE (2010)
Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells
Alison M. Paterson et al.
NATURE IMMUNOLOGY (2010)
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
Jamie B. Spangler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Robert Mabry et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Combination of CTL-associated Antigen-4 Blockade and Depletion of CD25+ Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell-based Vaccine in a Mouse Model of Colon Cancer
Asim Saha et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2010)
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Paolo A. Ascierto et al.
SEMINARS IN ONCOLOGY (2010)
Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice
Laura P. Stabile et al.
Cancers (2010)
Targeting the ANGPT-TIE2 pathway in malignancy
Hanhua Huang et al.
NATURE REVIEWS CANCER (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
Eph receptors and ephrins in cancer: bidirectional signalling and beyond
Elena B. Pasquale
NATURE REVIEWS CANCER (2010)
The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis A Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral Tongue
Daisuke Sano et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2009)
VEGFRs and Notch: a dynamic collaboration in vascular patterning
Lars Jakobsson et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
D. D. Meira et al.
BRITISH JOURNAL OF CANCER (2009)
Trastuzumab-induced HER Reprogramming in Resistant Breast Carcinoma Cells
Murli Narayan et al.
CANCER RESEARCH (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Devalingam Mahalingam et al.
CANCER TREATMENT REVIEWS (2009)
DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency
Timothy Hoey et al.
CELL STEM CELL (2009)
Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2009)
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Evelyn Yao et al.
CLINICAL CANCER RESEARCH (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Deirdre O'Mahony et al.
CLINICAL CANCER RESEARCH (2009)
Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway
Debora Dummer Meira et al.
EUROPEAN JOURNAL OF CANCER (2009)
Interaction of antibodies with ErbB receptor extracellular regions
Karl R. Schmitz et al.
EXPERIMENTAL CELL RESEARCH (2009)
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
Ji-Liang Li et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties IMPLICATIONS FOR MECHANISM OF ACTION IN VIVO
Adam Doern et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators
Nazzareno Dimasi et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts
Bachchu Lal et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma
Chong-Feng Gao et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR
Jennifer S. Michaelson et al.
MABS (2009)
Probabilities of success for antibody therapeutics
Janice M. Reichert
MABS (2009)
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
Brian T. Fife et al.
NATURE IMMUNOLOGY (2009)
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
Hellmut G. Augustin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
Y. Li et al.
ONCOGENE (2009)
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Nathan A. Pennell et al.
ONCOLOGIST (2009)
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Madeleine Hewish et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Jenny Bostrom et al.
SCIENCE (2009)
Development of a Fully Human Anti-PDGFR beta Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody
Juqun Shen et al.
NEOPLASIA (2009)
Discovery of Fully Human Anti-MET Monoclonal Antibodies with Antitumor Activity against Colon Cancer Tumor Models In Vivo
Edward van der Horst et al.
NEOPLASIA (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis
G. Thurston et al.
BRITISH JOURNAL OF CANCER (2008)
Durable Complete Responses From Therapy With Combined Epratuzumab and Rituximab Final Results From an International Multicenter, Phase 2 Study in Recurrent, Indolent, Non-Hodgkin Lymphoma
John P. Leonard et al.
CANCER (2008)
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425
Vishal Kamat et al.
CANCER BIOLOGY & THERAPY (2008)
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization
Judith Schmiedel et al.
CANCER CELL (2008)
Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000)
Joan H. Schiller
CANCER INVESTIGATION (2008)
A central role for HER3 in HER2-amplified breast cancer:: implications for targeted therapy
Si Tuen Lee-Hoeflich et al.
CANCER RESEARCH (2008)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer
Chia C. Portera et al.
CLINICAL CANCER RESEARCH (2008)
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
Karl S. Peggs et al.
IMMUNOLOGICAL REVIEWS (2008)
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Andrea Molckovsky et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2008)
IGF-1 Receptor Inhibitors in Clinical Trials-Early Lessons
S. John Weroha et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
Thomas Bachleitner-Hofmann et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons
Thomas Elter et al.
Current Hematologic Malignancy Reports (2008)
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma
Manzurul A. Sikder et al.
Current Hematologic Malignancy Reports (2008)
The reverse stop-signal model for CTLA4 function
Christopher E. Rudd
NATURE REVIEWS IMMUNOLOGY (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer et al.
NATURE REVIEWS CANCER (2008)
Integrins in angiogenesis and lymphangiogenesis
Christie J. Avraamides et al.
NATURE REVIEWS CANCER (2008)
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Dylan Daniel et al.
BLOOD (2007)
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer
Deirdre J. Cohen et al.
CLINICAL BREAST CANCER (2007)
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts
H. Toni Jun et al.
CLINICAL CANCER RESEARCH (2007)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines
David R. Emlet et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
David R. Clemmons
NATURE REVIEWS DRUG DISCOVERY (2007)
IMC-A12, a human IgG, monoclonal antibody to the insulin-like growth factor I receptor
Eric K. Rowinsky et al.
CLINICAL CANCER RESEARCH (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
Y. Kawaguchi et al.
BRITISH JOURNAL OF CANCER (2007)
Augmented antitumor activity against B-Cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20
Sreeram Maddipatla et al.
CLINICAL CANCER RESEARCH (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
J. P. Leonard et al.
ANNALS OF ONCOLOGY (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells
Elizabeth Half et al.
CANCER LETTERS (2007)
An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody
Juqun Shen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
Christel Larbouret et al.
CLINICAL CANCER RESEARCH (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Gavin Thurston et al.
NATURE REVIEWS CANCER (2007)
Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia
Jennifer Y. Zhang et al.
CANCER RESEARCH (2007)
The EGF receptor interacts with the type 1 IGF receptor and regulates its stability
Johann Riedemann et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Costimulation, coinhibition and cancer
Brant A. Inman et al.
CURRENT CANCER DRUG TARGETS (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma
Raymond I. Cruz et al.
LEUKEMIA & LYMPHOMA (2007)
Bispecific antibodies: Molecules that enable novel therapeutic strategies
Nicolas Fischer et al.
PATHOBIOLOGY (2007)
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth
Qi Pan et al.
CANCER CELL (2007)
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
Michelle A. Fanale et al.
DRUGS (2007)
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
John Ridgway et al.
NATURE (2006)
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member
Jennifer M. O'Toole et al.
CANCER RESEARCH (2006)
The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?
Ethan M. Shevach et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity
Ergun Kocak et al.
CANCER RESEARCH (2006)
Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis
Kristen N. Ganjoo et al.
LEUKEMIA & LYMPHOMA (2006)
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy
JR Tonra et al.
CLINICAL CANCER RESEARCH (2006)
Inhibtion of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2
N Roberts et al.
CANCER RESEARCH (2006)
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts
KJ Kim et al.
CLINICAL CANCER RESEARCH (2006)
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts
JM du Manoir et al.
CLINICAL CANCER RESEARCH (2006)
Eradication of established tumors in mice by a combination antibody-based therapy
Tomoyasu Uno et al.
NATURE MEDICINE (2006)
Development of recombinant human polyclonal antibodies for the treatment of complex human diseases
Anne B. Tolstrup et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Lymphangiogenesis in development and human disease
K Alitalo et al.
NATURE (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K Ko et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Engineering novel binding proteins from nonimmunoglobulin domains
HK Binz et al.
NATURE BIOTECHNOLOGY (2005)
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity
RM Perera et al.
CLINICAL CANCER RESEARCH (2005)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin
K Lamszus et al.
CLINICAL CANCER RESEARCH (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts
L Goetsch et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor
TG Johns et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
R Stein et al.
BLOOD (2004)
Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C
K Persaud et al.
JOURNAL OF CELL SCIENCE (2004)
Signalling by the type 1 insulin-like growth factor receptor: Interplay with the epidermal growth factor receptor
TE Adams et al.
GROWTH FACTORS (2004)
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation
YW Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
HS Cho et al.
NATURE (2003)
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model
YD Jung et al.
EUROPEAN JOURNAL OF CANCER (2002)
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
RM Shaheen et al.
BRITISH JOURNAL OF CANCER (2001)
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models
B Cao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo
XH Xin et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Stability engineering of antibody single-chain Fv fragments
A Wörn et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
D Ito et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
